CONTINUATION OF ANGINA DRUG TRIAL GETS GO-AHEAD

Corautus Genetics has reported that the independent data monitoring committee (DMC) has recommended, as the result of its second scheduled interim safety analysis, the continuation of GENASIS ("Genetic Angiogenic Stimulation Investigational Study").

GENASIS is Corautus' Phase IIb clinical trial to evaluate the safety and efficacy of Vascular Endothelial Growth Factor-2 (VEGF-2) for the treatment of patients with severe angina.

This planned interim safety analysis was conducted after the first 115 patients were treated in the trial. This was the second positive interim safety analysis recommendation by the DMC. The DMC, a group of independent physicians and a statistician, was established to monitor the safety data from the trial. Based upon their review of the available data, the DMC recommended continuing the GENASIS trial.